| Identification | Back Directory | [Name]
NNC 61-0029 | [CAS]
222834-30-2 | [Synonyms]
NNC 61-0029
(-)-DRF-2725
WMUIIGVAWPWQAW-DEOSSOPVSA-N
Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (αS)- | [Molecular Formula]
C25H25NO5 | [MOL File]
222834-30-2.mol | [Molecular Weight]
419.48 |
| Hazard Information | Back Directory | [Uses]
Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic. | [References]
[1] Chakrabarti R, Vikramadithyan RK, Misra P, et al. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol. 2003;140(3):527-537. DOI:10.1038/sj.bjp.0705463
[2] Saad MF, Greco S, Osei K, et al. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care. 2004;27(6):1324-1329. DOI:10.2337/diacare.27.6.1324 |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|